

Henrik Grønberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2908998/publications.pdf>

Version: 2024-02-01

142
papers

17,506
citations

53660

45
h-index

16127

124
g-index

148
all docs

148
docs citations

148
times ranked

27804
citing authors

#	ARTICLE	IF	CITATIONS
1	Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge. <i>Nature Medicine</i> , 2022, 28, 154-163.	15.2	143
2	Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study. <i>European Urology</i> , 2022, 82, 12-19.	0.9	4
3	Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 755-761.	2.0	14
4	Clinical Trial Protocol for ProBio: An Outcome-adaptive and Randomised Multiarm Biomarker-driven Study in Patients with Metastatic Prostate Cancer. <i>European Urology Focus</i> , 2022, 8, 1617-1621.	1.6	7
5	A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study. <i>European Urology Open Science</i> , 2022, 38, 32-39.	0.2	2
6	Association of 5 α -Reductase Inhibitors With Prostate Cancer Mortality. <i>JAMA Oncology</i> , 2022, 8, 1019.	3.4	18
7	Transcriptome-wide prediction of prostate cancer gene expression from histopathology images using co-expression-based convolutional neural networks. <i>Bioinformatics</i> , 2022, 38, 3462-3469.	1.8	9
8	Predictors of adverse pathology on radical prostatectomy specimen in men initially enrolled in active surveillance for low-risk prostate cancer. <i>World Journal of Urology</i> , 2021, 39, 1797-1804.	1.2	10
9	Ethnic variation in prostate cancer detection: a feasibility study for use of the Stockholm3 test in a multiethnic U.S. cohort. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 120-127.	2.0	5
10	Biomarker discrimination and calibration with MRI-targeted biopsies: an analysis with the Stockholm3 test. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 457-464.	2.0	1
11	Incorporating Magnetic Resonance Imaging and Biomarkers in Active Surveillance Protocols - Results From the Prospective Stockholm3 Active Surveillance Trial (STHLM3AS). <i>Journal of the National Cancer Institute</i> , 2021, 113, 632-640.	3.0	9
12	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , 2021, 53, 65-75.	9.4	264
13	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 532-541.	2.0	16
14	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. <i>Nature Communications</i> , 2021, 12, 1236.	5.8	40
15	The STHLM3-model, Risk-based Prostate Cancer Testing Identifies Men at High Risk Without Inducing Negative Psychosocial Effects. <i>European Urology Open Science</i> , 2021, 24, 43-51.	0.2	2
16	Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms. <i>European Urology Open Science</i> , 2021, 24, 11-16.	0.2	2
17	Challenging conventional karyotyping by next-generation karyotyping in 281 intensively treated patients with AML. <i>Blood Advances</i> , 2021, 5, 1003-1016.	2.5	12
18	Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 1588.	1.7	1

#	ARTICLE	IF	CITATIONS
19	KLK3 SNP-SNP interactions for prediction of prostate cancer aggressiveness. <i>Scientific Reports</i> , 2021, 11, 9264.	1.6	5
20	Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. <i>European Urology Oncology</i> , 2021, 4, 570-579.	2.6	38
21	MRI-Targeted or Standard Biopsy in Prostate Cancer Screening. <i>New England Journal of Medicine</i> , 2021, 385, 908-920.	13.9	184
22	Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. <i>Lancet Oncology</i> , The, 2021, 22, 1240-1249.	5.1	83
23	Intensity of Active Surveillance and Transition to Treatment in Men with Low-risk Prostate Cancer. <i>European Urology Oncology</i> , 2020, 3, 640-647.	2.6	15
24	Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: a population-based, diagnostic study. <i>Lancet Oncology</i> , The, 2020, 21, 222-232.	5.1	364
25	Identification and Validation of Leucine-rich $\hat{\pm}$ -2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification. <i>European Urology Open Science</i> , 2020, 21, 51-60.	0.2	13
26	Prognostic value of perineural invasion in prostate needle biopsies: a population-based study of patients treated by radical prostatectomy. <i>Journal of Clinical Pathology</i> , 2020, 73, 630-635.	1.0	9
27	A Nordic initiative for a more personal and accurate diagnostic pathway for prostate cancer. <i>Scandinavian Journal of Primary Health Care</i> , 2020, 38, 249-250.	0.6	2
28	The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. <i>Cancers</i> , 2020, 12, 3254.	1.7	16
29	Integrated transcriptomic and genomic analysis improves prediction of complete remission and survival in elderly patients with acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2020, 10, 67.	2.8	6
30	The effect of sample size on polygenic hazard models for prostate cancer. <i>European Journal of Human Genetics</i> , 2020, 28, 1467-1475.	1.4	14
31	A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1731-1738.	1.1	27
32	The ProBio trial: molecular biomarkers for advancing personalized treatment decision in patients with metastatic castration-resistant prostate cancer. <i>Trials</i> , 2020, 21, 579.	0.7	16
33	Lower urinary tract symptoms (LUTS) are not associated with an increased risk of prostate cancer in men 50-69 years with PSA $\hat{\pm}$ 3%ng/ml. <i>Scandinavian Journal of Urology</i> , 2020, 54, 1-6.	0.6	11
34	The economic burden of prostate cancer - a Swedish prevalence-based register study. <i>BMC Health Services Research</i> , 2020, 20, 448.	0.9	19
35	Has the PROPHECY of AR-V7 Been Fulfilled?. <i>Journal of Clinical Oncology</i> , 2019, 37, 2181-2182.	0.8	7
36	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. <i>European Urology</i> , 2019, 76, 831-842.	0.9	148

#	ARTICLE	IF	CITATIONS
37	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	5.8	88
38	Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? - protocol of the randomised study STHLM3MRI. <i>BMJ Open</i> , 2019, 9, e027816.	0.8	11
39	Are Prostate Specific-Antigen (PSA) and age associated with the risk of ISUP Grade 1 prostate cancer? Results from 72 996 individual biopsy cores in 6 083 men from the Stockholm3 study. <i>PLoS ONE</i> , 2019, 14, e0218280.	1.1	7
40	A Unified Prostate Cancer Risk Prediction Model Combining the Stockholm3 Test and Magnetic Resonance Imaging. <i>European Urology Oncology</i> , 2019, 2, 490-496.	2.6	13
41	Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in <i>TP53</i> Wild-Type Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2019, 5, 1060.	3.4	17
42	Somatic alterations detected in diagnostic prostate biopsies provide an inadequate representation of multifocal prostate cancer. <i>Prostate</i> , 2019, 79, 920-928.	1.2	9
43	The impact of different prostate-specific antigen (PSA) testing intervals on Gleason score at diagnosis and the risk of experiencing false-positive biopsy recommendations: a population-based cohort study. <i>BMJ Open</i> , 2019, 9, e027958.	0.8	15
44	A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry data. <i>PLoS ONE</i> , 2019, 14, e0211918.	1.1	10
45	The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 137-142.	2.0	20
46	Prevalence of <i>BRCA1</i> and <i>BRCA2</i> pathogenic variants in a large, unselected breast cancer cohort. <i>International Journal of Cancer</i> , 2019, 144, 1195-1204.	2.3	31
47	<i>TP53</i> Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 1766-1773.	3.2	117
48	Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 208-216.	1.1	21
49	Reply to Erik Rud, Peter Lauritzen, and Eduard Baco's Letter to the Editor re: Henrik Gränberg, Martin Eklund, Wolfgang Pickler, et al. Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. <i>Eur Urol</i> 2018;74:722â€8. <i>European Urology</i> , 2019, 75, e104-e105.	0.9	0
50	Response to Walsh. <i>Journal of the National Cancer Institute</i> , 2019, 111, 748-748.	3.0	0
51	Poor Follow-up After Elevated Prostate-specific Antigen Tests: A Population-based Cohort Study. <i>European Urology Focus</i> , 2019, 5, 842-848.	1.6	4
52	Development and Validation of a Novel RNA Sequencingâ€Based Prognostic Score for Acute Myeloid Leukemia. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1094-1101.	3.0	15
53	The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. <i>European Urology</i> , 2018, 74, 204-210.	0.9	68
54	Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 57-63.	2.0	134

#	ARTICLE	IF	CITATIONS
55	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. <i>British Journal of Cancer</i> , 2018, 118, 266-276.	2.9	12
56	Reply to Ola Bratt and Anna Åfverholm's Letter to the Editor re: Peter Stråm, Tobias Nordstråm, Henrik Grånberg, Martin Eklund. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2017.12.028 . <i>European Urology</i> , 2018, 74, e10-e11.	0.9	0
57	Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. <i>BMJ: British Medical Journal</i> , 2018, 360, j5757.	2.4	153
58	Risk of Prostate Cancer in Men Treated With 5 α -Reductase Inhibitors—A Large Population-Based Prospective Study. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1216-1221.	3.0	27
59	Balancing Overdiagnosis and Early Detection of Prostate Cancer using the Stockholm-3 Model. <i>European Urology Focus</i> , 2018, 4, 385-387.	1.6	9
60	The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50–69 yr Compared with Current Prostate Cancer Testing. <i>European Urology Focus</i> , 2018, 4, 707-710.	1.6	42
61	Summary statement on screening for prostate cancer in Europe. <i>International Journal of Cancer</i> , 2018, 142, 741-746.	2.3	29
62	Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis. <i>Genome Medicine</i> , 2018, 10, 85.	3.6	94
63	Germline variation at 8q24 and prostate cancer risk in men of European ancestry. <i>Nature Communications</i> , 2018, 9, 4616.	5.8	43
64	Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging. <i>European Urology</i> , 2018, 74, 722-728.	0.9	70
65	Predictors of participation in risk-based prostate cancer screening. <i>PLoS ONE</i> , 2018, 13, e0200409.	1.1	12
66	Re: Tobias Nordstråm, Andrew Vickers, Melissa Assel, Hans Lilja, Henrik Grånberg, Martin Eklund. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. <i>Eur Urol</i> 2015;68:139–46. <i>European Urology</i> , 2018, 74, e35-e36.	0.9	2
67	Effects of pre-notification, invitation length, questionnaire length and reminder on participation rate: a quasi-randomised controlled trial. <i>BMC Medical Research Methodology</i> , 2018, 18, 3.	1.4	27
68	Expression levels of long non-coding RNAs are prognostic for AML outcome. <i>Journal of Hematology and Oncology</i> , 2018, 11, 52.	6.9	43
69	AA9int: SNP interaction pattern search using non-hierarchical additive model set. <i>Bioinformatics</i> , 2018, 34, 4141-4150.	1.8	3
70	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. <i>Nature Genetics</i> , 2018, 50, 928-936.	9.4	652
71	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. <i>Nature Communications</i> , 2018, 9, 2256.	5.8	88
72	SNP interaction pattern identifier (SIPI): an intensive search for SNP–SNP interaction patterns. <i>Bioinformatics</i> , 2017, 33, 822-833.	1.8	11

#	ARTICLE	IF	CITATIONS
73	Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns. <i>European Urology</i> , 2017, 72, 192-200.	0.9	106
74	E-Science technologies in a workflow for personalized medicine using cancer screening as a case study. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2017, 24, 950-957.	2.2	4
75	Genetic profile of ductal adenocarcinoma of the prostate. <i>Human Pathology</i> , 2017, 69, 1-7.	1.1	20
76	Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer. <i>Molecular Oncology</i> , 2017, 11, 1413-1429.	2.1	20
77	Detection of Prostate Cancer Using a Multistep Approach with Prostate-specific Antigen, the Stockholm 3 Test, and Targeted Biopsies: The STHLM3 MRI Project. <i>European Urology Focus</i> , 2017, 3, 526-528.	1.6	14
78	Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. <i>British Journal of Cancer</i> , 2017, 117, 734-743.	2.9	7
79	Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis. <i>International Journal of Cancer</i> , 2017, 140, 322-328.	2.3	17
80	Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. <i>European Urology</i> , 2017, 72, 22-31.	0.9	37
81	Future directions in prostate cancer testing: a comment upon results from the prospective population-based diagnostic STHLM3 study. Gränberg H et al. <i>Lancet Oncology</i> . 2015 Nov 9; doi:10.1016/S1470-2045(15)00361-7. <i>World Journal of Urology</i> , 2017, 35, 895-896.	1.2	0
82	Molecular Differences between Screen-Detected and Interval Breast Cancers Are Largely Explained by PAM50 Subtypes. <i>Clinical Cancer Research</i> , 2017, 23, 2584-2592.	3.2	15
83	Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study. <i>International Journal of Cancer</i> , 2017, 140, 75-85.	2.3	28
84	Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy. <i>BMC Urology</i> , 2017, 17, 92.	0.6	3
85	Differential impact of RB status on E2F1 reprogramming in human cancer. <i>Journal of Clinical Investigation</i> , 2017, 128, 341-358.	3.9	83
86	Prevalence and heterogeneity of androgen receptor splice variants and intra-AR structural variation in patient with castration-resistant prostate cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 11530-11530.	0.8	0
87	The In Vitro Stability of Circulating Tumour DNA. <i>PLoS ONE</i> , 2016, 11, e0168153.	1.1	18
88	Body mass index in relation to serum prostate-specific antigen levels and prostate cancer risk. <i>International Journal of Cancer</i> , 2016, 139, 50-57.	2.3	25
89	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016, 53, 800-811.	1.5	174
90	Sequencing-based breast cancer diagnostics as an alternative to routine biomarkers. <i>Scientific Reports</i> , 2016, 6, 38037.	1.6	17

#	ARTICLE	IF	CITATIONS
91	Total antioxidant intake and prostate cancer in the Cancer of the Prostate in Sweden (CAPS) study. A case control study. <i>BMC Cancer</i> , 2016, 16, 438.	1.1	16
92	Study design requirements for RNA sequencing-based breast cancer diagnostics. <i>Scientific Reports</i> , 2016, 6, 20200.	1.6	2
93	The STHLM3 prostate cancer diagnostic study: calibration, clarification, and comments. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 394-394.	12.5	7
94	Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. <i>Cancer Research</i> , 2016, 76, 5103-5114.	0.4	100
95	Polyunsaturated fatty acids and prostate cancer risk: a Mendelian randomisation analysis from the PRACTICAL consortium. <i>British Journal of Cancer</i> , 2016, 115, 624-631.	2.9	23
96	Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels. <i>International Journal of Cancer</i> , 2016, 139, 1520-1533.	2.3	26
97	Telomere structure and maintenance gene variants and risk of five cancer types. <i>International Journal of Cancer</i> , 2016, 139, 2655-2670.	2.3	43
98	Blood lipids and prostate cancer: a Mendelian randomization analysis. <i>Cancer Medicine</i> , 2016, 5, 1125-1136.	1.3	68
99	Repeat Prostate-Specific Antigen Tests Before Prostate Biopsy Decisions. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw165.	3.0	13
100	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016, 6, 1052-1067.	7.7	157
101	Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. <i>Nature Communications</i> , 2016, 7, 10979.	5.8	50
102	Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort. <i>BMC Medicine</i> , 2016, 14, 66.	2.3	42
103	Determining breast cancer histological grade from RNA-sequencing data. <i>Breast Cancer Research</i> , 2016, 18, 48.	2.2	34
104	Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels. <i>Molecular Oncology</i> , 2016, 10, 825-837.	2.1	20
105	A population-based study on the association between educational length, prostate-specific antigen testing and use of prostate biopsies. <i>Scandinavian Journal of Urology</i> , 2016, 50, 104-109.	0.6	15
106	Gene regulatory mechanisms underpinning prostate cancer susceptibility. <i>Nature Genetics</i> , 2016, 48, 387-397.	9.4	119
107	The roles of stress and social support in prostate cancer mortality. <i>Scandinavian Journal of Urology</i> , 2016, 50, 47-55.	0.6	16
108	Public interest in and acceptability of the prospect of risk-stratified screening for breast and prostate cancer. <i>Acta Oncologica</i> , 2016, 55, 45-51.	0.8	39

#	ARTICLE	IF	CITATIONS
109	The risk-based STHLM3 model to improve prostate cancer testing in men 50-69 years: Further health, economic, and clinic evaluation.. <i>Journal of Clinical Oncology</i> , 2016, 34, 36-36.	0.8	0
110	Association of changing prostate-specific antigen (PSA) levels on repeat testing with lower risk for Gleason Score (GS) \geq 7 prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 284-284.	0.8	0
111	Polymorphisms In The Nitric-Oxide Synthase 2 Gene And Prostate Cancer Pathogenesis. <i>Redox Biology</i> , 2015, 5, 419.	3.9	5
112	Prediction of individual genetic risk to prostate cancer using a polygenic score. <i>Prostate</i> , 2015, 75, 1467-1474.	1.2	54
113	Body mass index and mortality in men with prostate cancer. <i>Prostate</i> , 2015, 75, 1129-1136.	1.2	37
114	The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study. <i>PLoS Genetics</i> , 2015, 11, e1005378.	1.5	331
115	Genetic studies of body mass index yield new insights for obesity biology. <i>Nature</i> , 2015, 518, 197-206.	13.7	3,823
116	A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. <i>Cancer Discovery</i> , 2015, 5, 368-379.	7.7	56
117	Tracking the Origin of Metastatic Prostate Cancer. <i>European Urology</i> , 2015, 67, 819-822.	0.9	79
118	The risk of prostate cancer for men on aspirin, statin or antidiabetic medications. <i>European Journal of Cancer</i> , 2015, 51, 725-733.	1.3	61
119	Ovarian Cancer Risk After Salpingectomy: A Nationwide Population-Based Study. <i>Journal of the National Cancer Institute</i> , 2015, 107, dju410-dju410.	3.0	300
120	Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. <i>European Urology</i> , 2015, 68, 139-146.	0.9	156
121	Genetic determinants of telomere length and risk of common cancers: a Mendelian randomization study. <i>Human Molecular Genetics</i> , 2015, 24, 5356-5366.	1.4	128
122	Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions. <i>Human Molecular Genetics</i> , 2015, 24, 5603-5618.	1.4	50
123	Two susceptibility loci identified for prostate cancer aggressiveness. <i>Nature Communications</i> , 2015, 6, 6889.	5.8	88
124	The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. <i>Cancer Causes and Control</i> , 2015, 26, 1603-1616.	0.8	77
125	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. <i>Human Molecular Genetics</i> , 2015, 24, 5589-5602.	1.4	67
126	Genome-Wide Association Study of Prostate Cancer-Specific Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1796-1800.	1.1	27

#	ARTICLE	IF	CITATIONS
127	A differential protein solubility approach for the depletion of highly abundant proteins in plasma using ammonium sulfate. <i>Analyst</i> , The, 2015, 140, 8109-8117.	1.7	20
128	Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study. <i>Lancet Oncology</i> , The, 2015, 16, 1667-1676.	5.1	308
129	Physical Activity and Survival among Men Diagnosed with Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 57-64.	1.1	115
130	Fine-Mapping the HOXB Region Detects Common Variants Tagging a Rare Coding Allele: Evidence for Synthetic Association in Prostate Cancer. <i>PLoS Genetics</i> , 2014, 10, e1004129.	1.5	34
131	A Genetic Score Can Identify Men at High Risk for Prostate Cancer Among Men With Prostate-Specific Antigen of 1–3 ng/ml. <i>European Urology</i> , 2014, 65, 1184-1190.	0.9	32
132	Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study. <i>European Urology</i> , 2014, 66, 489-499.	0.9	195
133	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. <i>Nature Genetics</i> , 2014, 46, 1103-1109.	9.4	408
134	Defining the role of common variation in the genomic and biological architecture of adult human height. <i>Nature Genetics</i> , 2014, 46, 1173-1186.	9.4	1,818
135	Evaluation of Exome Sequencing to Estimate Tumor Burden in Plasma. <i>PLoS ONE</i> , 2014, 9, e104417.	1.1	25
136	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. <i>Nature Genetics</i> , 2013, 45, 385-391.	9.4	492
137	Mediterranean Diet Score and prostate cancer risk in a Swedish population-based case–control study. <i>Journal of Nutritional Science</i> , 2013, 2, e15.	0.7	32
138	Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. <i>Nature Genetics</i> , 2010, 42, 937-948.	9.4	2,634
139	Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. <i>Nature Genetics</i> , 2008, 40, 281-283.	9.4	357
140	A common variant associated with prostate cancer in European and African populations. <i>Nature Genetics</i> , 2006, 38, 652-658.	9.4	738
141	Adjuvant chemotherapy in colorectal cancer: A joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. <i>Acta Oncologica</i> , 2005, 44, 904-912.	0.8	94
142	DGGE screening of mutations in mismatch repair genes (hMSH2 and hMLH1) in 34 Swedish families with colorectal cancer. <i>Clinical Genetics</i> , 1998, 53, 131-135.	1.0	19